Vifor good for Q4 filing, but can it vie for market?
This article was originally published in Scrip
Executive Summary
Vifor Pharma and Fresenius Medical Care Renal Pharma (a Galenica/Fresenius joint Venture) are planning regulatory filings for their hyperphosphataemia drug PA21 in the US, EU and Switzerland, starting in the fourth quarter and based on positive Phase III data. But if successful, the product will be entering a fairly saturated generics market, raising questions over its commercial potential.